澳大利亚和新西兰川崎病治疗管理的差异：对儿科医生的调查。
Variation in the management of Kawasaki disease in Australia and New Zealand: A survey of paediatricians.
机构信息
Department of General Medicine, The Sydney Children's Hospitals Network Randwick and Westmead, Sydney, New South Wales, Australia.
Children's Hospital Westmead Clinical School, Discipline of Child and Adolescent Health, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia.
出版信息
J Paediatr Child Health. 2021 May;57(5):646-652. doi: 10.1111/jpc.15290. Epub 2020 Dec 9.
AIM
This study aimed to describe the current management practices for Kawasaki disease (KD) in Australia and New Zealand.
METHODS
We performed a secondary analysis on the Australian and New Zealand responses to a large international survey of clinicians' perspectives on KD diagnosis and management.
RESULTS
There was general consensus among Australian and New Zealand clinicians regarding the indications for intravenous immunoglobulin and aspirin in the management of acute KD. There was less consensus on the dose of these agents, the definition and management of treatment-resistant KD and the approach to long-term thromboprophylaxis.
CONCLUSION
Most clinicians use intravenous immunoglobulin for primary treatment of KD. There is variation regarding other aspects of KD diagnosis and important management issues. Future studies should confirm whether this reported variation occurs in real-world practice and assess potential impacts on patient outcome.
目的
本研究旨在描述澳大利亚和新西兰目前对川崎病（KD）的管理实践。
方法
我们对澳大利亚和新西兰临床医生对 KD 诊断和管理的观点的大型国际调查的回答进行了二次分析。
结果
澳大利亚和新西兰临床医生在 KD 管理中静脉注射免疫球蛋白和阿司匹林的适应证方面普遍达成共识。在这些药物的剂量、难治性 KD 的定义和管理以及长期抗血栓形成预防的方法方面，共识较少。
结论
大多数临床医生使用静脉注射免疫球蛋白作为 KD 的主要治疗方法。KD 的其他诊断方面和重要管理问题存在差异。未来的研究应证实这种报告的差异是否存在于实际实践中，并评估对患者结局的潜在影响。
Zotero 插件